2333 lated BAF3 cells that are stably transfected with the G-CSF receptor. 2 To determine whether binding of G-CSF to endogenous G-CSF-R results in AKT activation, we performed Western blot analysis using phospho-AKT (Ser 473) antibody and NFS60 cell lysates pre-treated with or without 20 M PI3K inhibitor, LY294002. Our results demonstrated that AKT is phosphorylated at 5 and 15 min following G-CSF stimulation in the absence of LY294002 (Figure 1c ). However, activation of AKT in response to G-CSF is inhibited in the presence of LY294002 inhibitor (Figure 1c ). To test whether SRE-1 activation in response to G-CSF occurs through PI3 kinase, we stimulated cells with G-CSF and LY294002. We observed a statistically significant decrease in SRE-1 reporter activity (two-fold and 3.5-fold, respectively) at both 10 M and 20 M of LY294002 (P = 0.0214 and P = 0.008, respectively). These results suggest that the PI3K/AKT pathway also mediates activation of SRE-binding proteins in response to G-CSF stimulation.
G-CSF stimulation of NFS60 cells results in activation of PKC in a protein tyrosine kinase-dependent manner. 3 PKC is also strongly activated upon stimulation with 12-O-tetradecanoylphorbol-13-ester (TPA), resulting in the induction of immediate-early genes, such as cfos and egr-1. 6, 7 To test whether PKC is an upstream mediator of SRE-1 transcription in response to G-CSF, we stimulated cells with the PKC inhibitor bisindolymaleimide. Bisindolymaleimide (1 M) did not inhibit SRE-1 reporter activity in cells treated with G-CSF (P = 0.2603) ( Figure  1d ). However, we observed a statistically significant decrease in the fold induction of the p-480 egr-1-CAT in response to TPA stimulation with the addition of 1 M bisindolymaleimide compared to DMSO control (P = 0.0412). Therefore, G-CSF activates SRE-1 transcription in a PKCindependent manner.
Our results demonstrate that G-CSF mediates transcription of SRE-1 in NFS60 cells through activation of MEK and PI3K pathways, which converge upon SRE-binding proteins. PKC has been shown to activate SRE-binding proteins in response to serum, TPA and growth factors. 7, 8 Our data suggest that PKC does not activate SRE-binding proteins in response to G-CSF, suggesting that there are cytokine-specific pathways that lead to activation of SRE-binding proteins in myeloid cells. Furthermore, our findings clarify previously described G-CSF-induced signal transduction pathways by linking them to the activation of the SRE-1 motif in a myeloid cell line that expresses endogenous G-CSF receptors. 
Acknowledgements

TO THE EDITOR
Liver failure caused by reactivation of HBV is an infrequent complication after BMT, 1 although a few cases of fatal liver failure associated with HBV have been reported. 2 Recently, special attention has been paid to HBV precore mutant infection and fulminant hepatitis by HBV precore mutant has also been reported after BMT. 3, 4 We report here, an adolescent case of MDS infected by HBV precore mutant that was safely treated with unrelated BMT (U-BMT).
A reported. 5 In July 1995, she was found to be positive for HBV surface antigen (HBs Ag) during pre-BMT examination. At this time, she was positive for anti-HBV e antibody (HBe Ab) and anti-HBV core antibody (HBc Ab), and serum bilirubin and transaminase were normal. With retrospective analysis of cryopreserved sera, HBs Ag was negative in January 1995 and became positive in February 1995. Genomic analysis of infected HBV revealed precore mutant (T to G substitution at nucleotide(nt) 1815) which cannot produce HBe antigen (HBe Ag) because methionine (start codon) is changed to arginine. Although fulminant hepatitis by HBV precore mutant has also been reported after BMT, 3, 4 the frequency of hepatic events in HBs Ag-positive BMT patients was not found to be increased compared with that in HBs Ag-negative cases.
6,7 Then, we carried out U-BMT in August 1995 because of the severity of the primary disease. The preconditioning regimen consisted of cyclophosphamide 60 mg/kg once daily i.v. for 2 days (total 120 mg/kg) + total body irradiation 2 Gy twice daily for 3 days (total 12 Gy, six fractions) and GVHD prophylaxis included short-term MTX and continuous infusion of CsA. For antiviral therapy, aciclovir 250 mg twice a day i.v. (total 500 mg/day) was used for prophylaxis of herpes simplex virus infection as usual. We did not employ any special treatment for HBV other than close observation of liver function tests. She showed mild liver dysfunction after BMT and grade I acute GVHD was seen only in the skin. Engraftment was observed on day 23.
The results of sequential analysis of HBV associated laboratory tests are shown in Table 1 . As shown in HBV DNA polymerase activity, a substantial amount of HBV genome was observed in this case. The mutation at the precore region in this case (T to G substitution at nt 1815) is different from that in previously reported cases (G to A substitution at nt 1896). With the latter mutation, the palindromic structure of the precore portion is changed and the amount of HBV genome is reported to be markedly decreased. 8 However, a substantial amount of HBV genome was observed in this case despite the presence of HBe Ab. While HBe Ag was not produced with the mutation of the start codon in this case, the palindromic structure of the precore portion did not seem to be influenced and viral replication was considered to be maintained. This would be the reason why a substantial amount of HBV genome was observed in this case. Without special treatment for HBV, she was safely treated with U-BMT. Our patient developed no GVHD of the liver and hematological reconstitution was established. While BMT was safely performed in this case, the Table 1 Immunosuppressive therapy and HBV-associated laboratory data before and after BMT has not yet occurred. Clearance of HBs Ag after BMT was reported by Lau et al. 9 They also described that adoptive immunity transfer was observed only in BMT from HBs Ab-positive donors. In our case, the donor was negative for HBs Ag and HBs Ab and this would be the reason why seroconversion has not occurred. In addition, poor antigenicity of HBV precore mutant may have influenced seroconversion. In BMT for HBV carriers, it is very difficult to determine the duration and tapering of immunosuppressive treatment. If immunosuppression is too great, viral replication must increase and if its tapering is too rapid, fulminant hepatitis will occur with reconstituted immune system by BMT. We do not know the difference in the severity of hepatic events after BMT between patients with the nt 1815 mutant and those with the nt 1896 because there are no other reports on transplanted cases with HBV nt 1815 mutant. However, considering HBs Ag(+) and HBe Ab(+) status caused by this mutant, we thought some strategies were needed to avoid fluminant hepatitis after BMT. While our patient did not exhibit chronic GVHD, she has received CsA for 3 years with very slow tapering to avoid HBV reactivation and the rebound phenomenon. Although she developed insulin-dependent diabetes mellitus 6 months after BMT, this was probably due to secondary hemochromatosis (Figure 1) , and long-term treatment with CsA did not have any adverse effect. After the cessation of CsA, temporary elevation of HBV DNA polymerase activity was observed. There are several reports on the elevation of HBV DNA polymerase activity after the discontinuation of immunosuppressive agents or chemotherapy with or without fluminant hepatitis. 10, 11 We cannot explain this phenomenon properly; however, this was probably caused by the same mechanisms as in the reported cases.
We cannot determine whether our treatment is optimal; however, this patient has been well and free of disease for 80 months after BMT. Although we cannot explain the difference between the reported fatal cases with HBV precore mutant and ours entirely, our findings showed that HBV precore mutant infection is not an absolute contraindication for BMT. Very slow tapering of CsA may have contributed in avoiding critical hepatic events. We have shown the possibility of BMT for patients infected by HBV precore mutant. 
The myelodysplastic syndromes (MDS) are a heterogeneous group of blood neoplasms characterized by ineffective hemopoiesis and peripheral cytopenia, involving one or more of the non-lymphoid hemopoietic lineages and an increased tendency for evolution into acute leukemia. Although MDS are more often diagnosed in the elderly, clinically, morphologically and biologically similar diseases are also recognized in children. However, because of their lower incidence and clinical variability in the younger patient and the frequent overlap between the myelodysplastic and myeloproliferative syndromes, there is still considerable controversy on the most appropriate classification and optimal therapeutic approach for childhood MDS. During childhood, MDS frequently arise from inherited constitutional genetic disorders regarded as a background predisposing to the acquisition of genomic lesions or the appearance of other forms of hemopoietic dysfunction. At least 30% of them affect patients with pre-existing inherited genetic disorders, mainly immunodeficiency states, constitutional chromosomal syndromes, DNA repair deficiency conditions and congenital cytopenias. 1 Since the etiologic basis of myelodysplasia remains elusive, the study of such cases is expected to provide additional insight into the cascade of alterations leading to the dysplastic marrow failure.
We describe here two siblings with myelodysplastic syndrome and Naxos disease (ND). ND is an inherited disorder characterized by specific cardiac and cutaneous manifestations resulting from a genetically determined deficiency of plakoglobin, an essential protein component of intercellular junction. This constituent protein is involved in cell adherence and desmosomal junctions, thus having adhesive and signaling functions. 2 Although the cardinal symptoms of ND relate to the derangement of adhesive function, there is increasing evidence that plakoglobin is also involved in several other biological processes, including apoptosis 3 and tumor suppression. 4 We report, for the first time, an association between MDS and ND and discuss the possibility of a pathogenetic link between these two conditions. Case 1 was a 4.-year-old girl referred to our Department because of anorexia, fatigue and pallor during the last month, preceded only by one episode of a few days' fever. Her previous medical history was uneventful. There were no other physical findings except for pallor, mild cardiac arrhythmia and the cutaneous characteristics of ND phenotype, ie palmoplantar keratoderma and dense woolly hair. Her parents had a normal phenotype. Though she was hemodynamically stable, frequent ventricular extrasystoles of left bundle branch block configuration were recorded at rest and on 24-h electrocardiographic monitoring. Laboratory studies showed: (1) anemia with hemoglobin (Hb) 7.9 g/dl, hematocrit (Ht) 23.7%, MCV 103.5 fl, MCH 34.5 pg, MCHC 33.3 g/dl, reticulocytes 0.9%, hemoglobin A 2 1.9% and F 3.1%; (2) thrombocytopenia (PLT 30 000/l); and (3) myeloblasts in peripheral blood smear (white cell count (WBC) 10 400 ml with 48% hypogranulated polymorphonuclear neutrophils, 27% lymphocytes, 8% monocytes, 17% myeloblasts and two pyknotic erythroblasts per 100 WBCs). Repeated (three samples) bone marrow aspiration and biopsy showed a hypercellular marrow with erythroid and megakaryocytic dysplasia (micromegakaryocytes), mild increase of stroma reticular fibers and 15% myeloblasts expressing CD34, CD33 and CD117 on flow cytometry. Cytogenetic analysis on three consecutive bone marrow samples showed normal karyotype (46XX). On the basis of these findings, the diagnosis of refractory anemia with excess of blasts (MDS-RAEB) was established. Bone marrow transplantation was considered and her only brother was called in as a possible donor.
Case 2 was case No. 1's brother, a 13-year-old boy who on clinical examination presented with the characteristics of ND, ie woolly hair and a more extensive palmoplantar keratoderma. He had a history of a syncopal episode at the age of 12, and on clinical examination severe ventricular arrhythmia was evident. His electrocardiographic, echocardiographic and angiographic findings were compatible with arrhythmogenic right ventricular cardiomyopathy (ARVC), and the diagnosis was confirmed with endomyocardial biopsy. His arrhythmia was controlled with amiodarone. His hematological investigation revealed neutropenia (1400/l) and moderate macrocytosis. More specifically, peripheral blood tests showed: Hb 13.3 g/dl, Ht 42.1%, MCV 98 fl, MCH 31 pg, MCHC 31.6 g/dl, reticulocytes 1.8%, hemoglobin F 0.7%, WBC 4200/l with 32% hypogranulated polymorphonuclear neutrophils, 62% lymphocytes, 1% eosinophils, 5% monocytes and platelet count 298 000/l.
Apart from an episode of pneumonia at the age of 2 years, there was no history of other major infections. During that episode of pneumonia he had an adequate neutrophilic response (WBC 12 300/l with 70% neutrophils) while a blood count at the age of 4 was normal.
On two consecutive aspirations, the bone marrow was hypercellular with erythroid hyperplasia, a left shift of the granulocytic lineage, 5% myeloblasts and marked trilineage dysplasia, more prominent in the erythroid (multinuclearity, 'megaloblastoid' changes, cytoplasmic
